AXIS Clinicals Limited   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Los Angeles CA United States (2010)

Organization Overview

First Clinical Trial
2011
NCT01691456
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Axis Clinicals | AXIS Clinicals | Axis Clinicals Limited | Axis Clinical Trials | Medical Director, Axis Clinicals

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Arthritis (Phase 1)

Arthritis, Rheumatoid (Phase 1)

Atrophic Vaginitis (Phase 3)

Atrophy (Phase 3)

Diabetes Mellitus (Phase 2)

Diabetes Mellitus, Type 2 (Phase 2)

Gastrointestinal Diseases (Phase 3)

Hematologic Diseases (Phase 1)

Leishmaniasis (Phase 1)

Leishmaniasis, Visceral (Phase 1)

Lice Infestations (Phase 3)

Malnutrition (Phase 1)

Neoplasms (Phase 1)

Signs and Symptoms, Digestive (Phase 3)

Tissue Adhesions (Phase 1)

Vaginitis (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 19
  • # of Trial APIs: 23